Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547213 | 0.95 | EPHX1 (0.49) | EPHX1ALDH1A1RAB9AKMT2ANPC1 | |
| SCHEMBL2676319 | 0.95 | EPHX1 (0.49) | EPHX1ALDH1A1RAB9AKMT2ANPC1 | |
| SCHEMBL13809020 | 0.86 | ALDH1A1 (0.34) | EPHX1ALDH1A1RAB9AKMT2AMEN1 | |
| SCHEMBL13547356 | 0.86 | HTT (0.38) | EPHX1ALDH1A1RAB9AKMT2ANPC1 | |
| SCHEMBL13547377 | 0.85 | KDM4E (0.43) | ALDH1A1MAPTKDM4E | |
| SCHEMBL13547225 | 0.85 | KDM4E (0.46) | EPHX1ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3617697 | 0.84 | HTT (0.36) | EPHX1ALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL13547222 | 0.84 | KDM4E (0.45) | EPHX1ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL3612641 | 0.84 | HTT (0.36) | EPHX1ALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL13547226 | 0.83 | RAB9A (0.34) | EPHX1ALDH1A1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118111-B1 | 2-AMIN0-5, 7-DIHYDR0-6H- PYRROLO [3, 4-D] PYRIMIDINE DERIVATIVES AS HSP-90 INHIBITORS FOR TREATING CANCER | PFIZER (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | PFIZER INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | PFIZER INC. | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | HSP90AB2P, HSP90AB1, HSP90AA1 | EPHX1 2596/4885ALDH1A1 771/4885RAB9A 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.